| Uterine Fibroids
Lupron Depot vs Myfembree
Side-by-side clinical, coverage, and cost comparison for uterine fibroids.Deep comparison between: Lupron Depot vs Myfembree with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsMyfembree has a higher rate of injection site reactions vs Lupron Depot based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Myfembree but not Lupron Depot, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Lupron Depot
Myfembree
At A Glance
IM injection
Every 3 months
GnRH agonist
Oral
Daily
GnRH receptor antagonist
Indications
- Endometriosis
- Uterine Fibroids
- Uterine Fibroids
- Menorrhagia
- Endometriosis
Dosing
Endometriosis 11.25 mg IM every 3 months for 1 to 2 doses (up to 6 months); may be administered alone or with norethindrone acetate 5 mg daily add-back. Retreatment for up to 6 additional months requires norethindrone acetate add-back; total treatment duration must not exceed 12 months.
Uterine Fibroids One IM injection of 11.25 mg providing a single 3-month treatment course.
Uterine Fibroids, Menorrhagia One tablet orally once daily; start no later than seven days after menses onset; maximum treatment duration 24 months.
Endometriosis One tablet orally once daily; start no later than seven days after menses onset; maximum treatment duration 24 months.
Contraindications
- Hypersensitivity to GnRH, GnRH agonist analogs including leuprolide acetate, or any excipient in LUPRON DEPOT 11.25 mg
- Undiagnosed abnormal uterine bleeding
- Pregnancy
- When norethindrone acetate is co-administered, contraindications to norethindrone acetate also apply
- High risk of arterial, venous thrombotic, or thromboembolic disorders, including women over 35 who smoke, history of DVT or PE, vascular disease, thrombogenic valvular or rhythm disease, hypercoagulopathy, uncontrolled hypertension, or migraine headaches with aura if over 35
- Pregnancy
- Known osteoporosis
- Current or history of breast cancer or other hormone-sensitive malignancy, or increased risk for hormone-sensitive malignancies
- Known hepatic impairment or disease
- Undiagnosed abnormal uterine bleeding
- Known anaphylactic reaction, angioedema, or hypersensitivity to MYFEMBREE or any of its components
Adverse Reactions
Most common (>=5%) Hot flashes/sweats, headache, vaginitis, depression/emotional lability, general pain, weight gain/loss, nausea/vomiting, decreased libido, dizziness, acne, skin reactions
Serious Urinary tract infection, renal calculus, depression
Postmarketing Rash, urticaria, anaphylaxis, mood swings, depression, suicidal ideation, convulsion, peripheral neuropathy, serious liver injury, injection site reactions including induration/abscess/necrosis, spinal fracture, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke, pituitary apoplexy
Most common (>=3%) Headache, vasomotor symptoms, mood disorders, abnormal uterine bleeding, nausea, toothache, back pain, decreased sexual desire and arousal, arthralgia, fatigue, dizziness, alopecia, libido decreased
Serious Thromboembolic disorders and vascular events, bone loss, suicidal ideation and mood disorders, hepatic impairment and transaminase elevations, elevated blood pressure, uterine fibroid prolapse or expulsion, hypersensitivity reactions
Postmarketing Anaphylactoid reaction, drug eruption, angioedema, urticaria, uterine leiomyoma degeneration
Pharmacology
Long-acting GnRH agonist that causes initial stimulation followed by prolonged suppression of pituitary gonadotropins, resulting in decreased gonadal steroid secretion and quiescence of estrogen-dependent tissues; effect is reversible upon discontinuation.
GnRH receptor antagonist combination; relugolix competitively binds pituitary GnRH receptors to suppress LH and FSH, reducing ovarian estradiol and progesterone, while co-formulated estradiol mitigates bone loss and norethindrone acetate provides endometrial protection against unopposed estrogen.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Lupron Depot
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
Myfembree
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (6/12) · Qty limit (10/12)
UnitedHealthcare
Lupron Depot
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (2/8) · Qty limit (2/8)
Myfembree
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (4/8)
Humana
Lupron Depot
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (2/3)
Myfembree
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Lupron Depot.
$5/momo
Myfembree Copay Assistance ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Lupron DepotView full Lupron Depot profile
MyfembreeView full Myfembree profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.